Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare (Solifenacin) From Other Antimuscarinics
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2016
Price : $35 *
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms VEST
- Sponsors Astellas Pharma BV
- 12 Sep 2016 Status changed from active, no longer recruiting to completed.
- 25 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 29 Oct 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.